Nature interviewed our Co-founder Layla Hosseini-Gerami about using AI to identify and revive failed drugs to create new medicines with huge potential.
Layla shares the science behind our approach to drug turnaround, and the mission driving our work: identifying failed drugs with hidden potential, understanding and fixing the root cause of failure, and accelerating the process of bringing new therapies to the clinic and the patients who need them.
“We have built an AI-driven platform to identify failed drugs and fix their toxicity issues. First, it narrows down thousands of failed drugs to the most promising: the drugs that have huge potential to make a difference to patients but which have hit an unexpected safety issue; for example, causing toxicity in the liver. Next, we apply deep learning, combining bioinformatics, chemoinformatics and multimodal data to understand the root cause of the safety issue and to develop mitigation strategies. Our core aim is to take these drugs, make minimal chemical changes and get them back into the clinic as efficiently as possible.”
This article is part of Nature Spotlight: Drug discovery, which is looking at the challenges associated with the clinical trials pipeline, as well as the researchers employing artificial intelligence to help re-engineer failed therapies.
Read more:
'How I use AI to turn failed drugs into new medicines,' can be read in full at Nature
Published 17 November 2026 by Nature
